Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2012 Global Healthcare Conference on Thursday November 15, 2012 at 10:40 am (GMT) / 5:40 am (EST) in London.
A live webcast of the presentation will be available via the “Investor Relations” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical
products and topical gel-based medicines. The Company's technology
platforms include VIBEX™ disposable Medi-Jet, disposable multi-use pen
injectors and Vision™ reusable needle-free injectors marketed as Tjet
® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has
a multi-product deal with Teva that includes Tev-Tropin
human growth hormone (hGH), VIBEX epinephrine and several other
products. Antares Pharma’s partnership with Ferring includes Zomacton
hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a
treatment for overactive bladder that is marketed by Watson
Pharmaceuticals, Inc. Elestrin
® (estradiol gel) is FDA
approved for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and is marketed in the U.S. by Meda Pharma.
Antares Pharma has two facilities in the U.S. The Parenteral Products
Group located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices and
related disposables, and develops its disposable pressure-assisted VIBEX
Medi-Jet and pen injector systems. The Company’s corporate head office
and Product Development Group are located in Ewing, New Jersey.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV